Caris Life Sciences is a patient-centric, next-generation AI TechBio company and precision medicine pioneer that develops and commercializes innovative solutions through comprehensive molecular profiling and advanced AI and machine learning algorithms. The company provides comprehensive molecular profiling services analyzing DNA, RNA, and proteins to understand cancer at the molecular level, including MI Profile (whole exome and transcriptome sequencing for 23,000+ genes), Caris Assure (blood-based diagnostics), and AI-driven molecular tumor board reports. Caris has built one of the largest multimodal databases of combined molecular and clinical outcomes data with more than 740,000 matched patient records.
Caris Life Sciences is publicly traded
IPO'd on June 20, 2025
This company is no longer available on our private secondary market. Shares can be traded publicly under CAI.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2008
Employees
1,468–1,700
Total Funding
$2.35B
6 rounds
Last Private Valuation
$7.83B
April 7, 2025
Total raised $2.35B across 6 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series D (growth equity)
Date
May 11, 2021
Amount
$830M
Valuation
$7.83B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| April 7, 2025 | Pre-IPO growth equity | $168M | — | Braidwell LP |
| January 19, 2023 | Senior secured debt | $400M | — | OrbiMed, Braidwell |
| May 11, 2021 | Series D (growth equity) | $830M | $7.83B | Sixth Street |
David Dean Halbert
Founder, Chairman & CEO
Yes, Caris Life Sciences is publicly traded under the ticker symbol CAI on the NASDAQ. The company went public in June 20, 2025.
Caris Life Sciences trades under the ticker symbol CAI on the NASDAQ. It began trading in June 20, 2025.
Caris Life Sciences (CAI on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker CAI to place an order.
Caris Life Sciences went public in June 20, 2025 via ipo, with an offering valuation of approximately $7.83B. Caris Life Sciences completed its initial public offering on June 20, 2025, listing on the Nasdaq Global Select Market under ticker symbol CAI. The company priced 23,529,412 shares at $21.00 per share, raising $494.1 million. Shares began trading June 18, 2025, and surged 33% on the first day of trading. The company achieved a market valuation of $7.9 billion at IPO.
Caris Life Sciences raised $2.35B across 6 disclosed funding rounds prior to its public listing.
Caris Life Sciences was founded by David Dean Halbert in 2008.
Caris Life Sciences is headquartered in Irving, Texas, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.